A plan to expand the use of Acadia Pharmaceuticals’ only approved medicine to cover the treatment of patients with schizophrenia was dealt a setback on Monday with the failure of a late-stage clinical trial, the company said.

The Acadia drug, called Nuplazid, failed to improve the overall symptoms of schizophrenia compared with a placebo. The Phase 3 study enrolled nearly 400 schizophrenia patients with moderate to severe psychotic symptoms inadequately controlled by currently approved drugs. 

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • If I had schizophrenia, I would do a one time visit to a traditional Chinese medicine doctor. Usually in a local chinatown. Seems to be a lot more health in that country than here.

  • Does this imply that the neuropathology of Parkinson’s psychosis is different than the neuropathology of schizophrenia?

Comments are closed.

Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy